How to Develop the Highest Possible Leading-edge Interdisciplinary Care Model for People With MS, That Will be Relevant to All Stakeholders and Declinable to Different Local Contexts With the Ultimate Goal of Ensuring the Highest Level of Quality of Care in MS.
NCT07289724 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 57
Last updated 2026-04-13
Summary
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating and degenerative disease of the central nervous system. It is currently not curable, although several disease-modifying treatments (DMT) reduce the occurrence of relapses and slow disability progression. It affects about 2.8 million persons worldwide (1 million in Europe) with 3 women per 1 man. MS usually starts between 20 and 40 years old, and most people live with the disease for several decades, as life expectancy is reduced by 6-13 years compared to general population. Disease courses are highly heterogeneous and unpredictable at individual level. MS may lead to limited walking abilities but also to invisible symptoms: cognitive dysfunction, pain, bladder dysfunction, and fatigue. This results in a very high burden on affected persons, their families and society. Overall costs among 30 European countries were evaluated in 2010 to 14.559 million euros.
The chronic nature of MS implies a high level of use of health services during the entire life span. MS-specific therapeutic options have undergone extensive development since the 2000s, as well as the understanding of the usefulness of comprehensive MS care. The usual core component of MS care is the neurologist/general practitioner (GP) dyad, and only neurologists are allowed to prescribe MS-specific DMT. With the expanding therapeutic area (and the required strategies to prevent and minimize the risks of adverse events) combined with the heterogeneity of the course and the symptoms, it is more and more difficult for a single physician to acquire and maintain the expertise necessary to comply with gold standard care. Patients may also need referrals to other specialists (physiotherapists, neuropsychologists, psychiatrists, occupational therapists…) depending on their needs. They sometimes use the terms "labyrinth" or "obstacle course" to describe the complex, non-linear, multi-professionals' pathway they are facing.
In the past years, the concept of multidisciplinary MSCU emerged as an organisational innovation, and structures were established at different scales in several countries. These teams available in a single place provide the high level of expertise needed for complex cases or specific steps of the care process. They also dispense formalized diagnostic procedures, protocols for initiation and follow-up of DMT. Their organisation can vary across regions and healthcare systems and needs to be balanced with clinical practice according to local conditions. Thus, there are about 2450 neurologists (67% in public hospitals, 33% private practice) in France, and 23 MS expert centres were labeled by the Ministry of Health in 2017 (one per region, systematically in university public hospitals). In Italy, there are approximately 8000 neurologists and 240 MS centres of varying size, often located within neurology departments in public hospitals. The ability to coordinate interdisciplinary care in each MS centre depends on the capacity and quality of the local health and social care system. The presence of such a new actor in MS management leads to new questions regarding its role and place in the pre-existing system, and how the previous actors (mainly general neurologists, GP, people with MS) accept or use it. To date, little is known on the impact of MSCU on integrated care and personalized approach. Therefore, it is crucial to understand how key stakeholders, such as health professionals, payers and people affected by MS perceive this new and innovative element of the care pathway.
Conditions
Interventions
- OTHER
-
Focus group
With regard to focus groups, these group interviews will take place at specialist centres. Three CRC centres have agreed to host them on their premises. Groups of 6 to 8 people will be invited, the average duration of half a day, or approximately 3½ hours, including welcome and a break. In each of the three approved expert centres, there will be a group composed solely of patients and carers, followed by a group composed of healthcare professionals who are experts in MS, and finally a mixed group (i.e. three FG sessions and therefore three different half-days in each centre three centres).
- OTHER
-
individual interview
The semi-structured individual interview contains topics that have been thought out in advance, but their form and order are left to the flow of the interview. This type of interview takes the form of a conversation in order to reduce the artificial nature of the exchange. It is an interaction between the researcher and the interviewee whose experience is of direct interest to the research being conducted.
Sponsors & Collaborators
-
Assistance Publique - Hôpitaux de Paris
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-03-18
- Primary Completion
- 2026-09-30
- Completion
- 2026-09-30
Countries
- France
Study Locations
More Related Trials
-
Care in Multiple Sclerosis (MS)
NCT07011914 ·Status: RECRUITING
-
EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients
NCT02117375 ·Status: UNKNOWN ·Phase: NA
-
Impact of Multiple Sclerosis From the Viewpoint of the Caregivers
NCT02388334 ·Status: UNKNOWN
-
Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis
NCT05633875 ·Status: RECRUITING
-
Evaluation of the Impact of Lesions of the Motor and Proprioceptive Brain and Pan-medullary Pathways on Their Clinically and Electrophysiologically Assessed Function in Multiple Sclerosis
NCT04220814 ·Status: COMPLETED ·Phase: NA
-
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
NCT04873492 ·Status: RECRUITING ·Phase: NA
-
MRI Study of the Mechanisms Underlying Irreversible Disability in Multiple Sclerosis
NCT03356366 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
MEsenchymal StEm Cells for Multiple Sclerosis
NCT02403947 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
The Regulatory Role of miRNA 27 Follistatin Like Protein-1 Gene in Multiple Scelerosis
NCT06290453 ·Status: NOT_YET_RECRUITING
-
Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients
NCT02290587 ·Status: COMPLETED ·Phase: NA
-
Screening for Cognitive Disorders in Multiple Sclerosis
NCT07030036 ·Status: NOT_YET_RECRUITING
-
Measuring Consequences of Disability for Patients With Multiple Sclerosis and Caregivers on Economic Burden
NCT02592265 ·Status: COMPLETED
-
Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis
NCT01723631 ·Status: TERMINATED ·Phase: NA
-
Validation of the French Adaptation of the MSWDQ-23 Questionnaire
NCT04860791 ·Status: COMPLETED
-
Characterization of Cortical Injury in Early MS Patients: a 7T MRI Study
NCT03624296 ·Status: UNKNOWN ·Phase: NA
-
Digitalization of Neurofunctional Tests Via a Mobile Application DAMS for Multiple Sclerosis Patients
NCT03148938 ·Status: COMPLETED ·Phase: NA
-
Development of Digital Biomarkers in Multiple Sclerosis: Validation Study 2
NCT06309173 ·Status: WITHDRAWN
-
Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility
NCT07164924 ·Status: COMPLETED
-
Enhancing Quality of Life in MS Patients Through Tailored Therapeutic Education
NCT06450600 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Feasibility Study of a Relapse Investigation Questionnaire Administered by an MS Care Coordinator Nurse in Patients With Multiple Sclerosis
NCT06994026 ·Status: NOT_YET_RECRUITING
-
Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors (NEUROSEX)
NCT03154801 ·Status: UNKNOWN ·Phase: NA
-
Emotional Processing, Family Life, Friendship and Social Integration in Patients With Multiple Sclerosis
NCT02708927 ·Status: COMPLETED ·Phase: NA
-
Sexual Dysfunction in Patients With Relapsing Remitting Multiple Sclerosis and Associated Comorbidities
NCT04157283 ·Status: UNKNOWN
-
An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers
NCT01075737 ·Status: COMPLETED
-
Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis
NCT00134563 ·Status: COMPLETED ·Phase: PHASE3